

Indraprastha Medical Corporation Limited

Regd. Office: Sarita Vihar, Delhi-Mathura Road, New Delhi - 110 076. (INDIA)
Corporate Identity Number: L24232DL 1988PLC030958

Phone : 26925801, 26925858 Fax : 91-11-26825601

E-mail: asinghal@apollohospitals.com Website: apollohospdelhi.com



A. K. SINGHAL Vice President Cum Company Secretary

Ref.: IMCL/CS/BSE/BM/2017

14th November, 2017

The BSE Ltd., Phiroze Jeejebhoy Towers, Dalal Street, Mumbai – 400 001

Stock Code 532150

Sub.: Unaudited Financial Results for the quarter and half year ended 30th September, 2017

Dear Sir,

Enclosed please find a copy of the Unaudited Financial Results for the quarter and half year ended 30^{th} September, 2017, along with a copy of the Limited Review Report by the Auditors.

The Board Meeting ended at 05:25 pm.

This is for your information and record.

Thanking You,

Sincerely Yours,

Encl. as above

INDRAPRASTHA MEDICAL CORPORATION LIMITED

Registered office: Sarita Vihar, Delhi Mathura Road, New Delhi - 110076 Corporate Identity Number: L24232DL1988PLC030958

Corporate Identity Number: L24232DL1988PLC030958
E-maik imci@apollohospitals.com, Website: apollohospdelhi.com



Statement of Unaudited Financial Results for the Quarter and Half-Year ended 30th September, 2017

₁	···	 · · · 	-			Amoun	t (Rs. in Lacs)
	Particulars	Quarter ended			Half-Year ended		Financial Year ended
S. No.		30.09,2017 (Unaudited)	30.06.2017 (Unaudited)	30.09.2016 (Unaudited)	30.09.2017 (Unaudited)	30.09.2016 (Unaudited)	31.03.2017 (Audited)
1	Revenue from operations	19098.37	18423.51	19369.40	37521.88	38722.42	76571.62
2	Other Income	9.83	8.70	8.23	18.53	15.61	159.26
3	Total income	19108.20	18432.21	19377.63	37540.41	38738.03	76730.88
4	Expenses					i	
	a) Cost of material consumed	3629.24	3589.42	3786.20	7218.66	7598.73	15021.28
	b) Purchase of stock in trade	-	-	. ,	-	-	_
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		_	-	, -	-	.
	d) Employee benefits expense	4830.45	4623.61	4674.60	9454.06	9336,14	19025.71
	e) Consultation fee paid to Doctors	4933.25	4795.92	4804.02	9729.17	9723.83	19145.51
	f) Finance cost	230.27	212.21	189.58	442,48	359.77	790.54
	g) Depreciation and amortisation expense	777.38	758.80	742,34	1536.18	1473.38	3053.21
	h) Other expenses	3894.01	3723.79	4009.91	7617.80	78 30.06	15612.87
	Total expenses	18294.60	17703.75	18206.65	35998.35	36321.91	72649.12
5	Profit before exceptional items and tax	813,60	728.46	1170.98	1542.06	2416,12	4081.76
6	Exceptional items	_	-	-	-	-	-
7	Profit before tax (PBT)	813.60	728.46	1170,98	1542.06	2416.12	4081.76
8	Tax expense						
	Current tax	293.78	315.56	488,52	609.34	957.89	1854,11
	Deferred tax	(4.61)	(63.05)	(55.21)	(67.66)	(97,90)	(396.88)
9	Profit for the period after tax (PAT)	524.43	475.95	737.67	1000.38	1556.13	2624.53
10	Other comprehensive income						,
	a). (i) Items that will not be reclassified to profit or loss	24.12	7.43	(98,38)	31.55	(76.25)	106.14
1 •	(if) Income Tax relating to items that will not be reclassified to profit or loss	(8.35)	(2,57)	34.05	(10.92)	26.39	(36.73)
	Total other comprehensive income, Net of tax expenses	15.77	4.86	(64.33)	20.63	(49.86)	69,41
11	Total comprehensive income for the period	540.20	480.81	673.34	1021.01	1506.27	2693.94
12	Paid-up equity share capital (Face value Rs. 10/- each)	9167.30	9167.30	9167.30	9167.30	9167.30	9167.30
13	Earnings per share Bäšic and Dilutëd (Rs.)	0.57	0.52	0.80	1.09	1.70	2,86





	Statement of Assets and Liabilities:	,	t (Rs. in Lacs
			al
	Particulars	Unaudited	Audited
_	, ACRIMA	30.09.2017	31.03.2017
	ASSETS	ļ <u></u>	
1	Non-current assets	!	
	(a) Property, Plant and Equipment	29825.44	29389.3
	(b) Intangible Assets	150.21	183.6
	(c) Financial Assets	275.56	278.5
	(d) Other non-current Assets	228.46	198.
	·	30479.67	30050.3
,	Current assets		
-	(a) Inventories	857,41	004
	(b) Financial Assets	14,760	994.
	(i) Trade receivables	1001150	hroa .
		10914.53	9831.1
	(ii) Cash and cash equivalents	625.25	268,9
	(iii) Bank Balances other then (ii) above	2066,81	429.6
	(iv) Loans	42.33	36.0
	(v) Others	1844.81	1481.9
	(c) Current Tax Assets (Net)	1241.11	886.3
	(d) Other current assets	1503.20	
		19095,45	16188.9
\dashv	TOTAL OF ASSETS	49575.12	46239.2
_			
В.	EQUITY AND LIABILITIES		
1	Equity		
•	(a) Equity Share capital	9167.30	9167.3
	(b) Other Equity	12950.46	13915.4
	(o) Star Equity	22117.76	23082.7
		2217.70	25,002.7
	Liabilities		
2	Non-current liabilities		1
	(ä) Financial Liabilities]	
	(i) Borrowings	2400.00	-
	(ii) Other Financial liabilities	268,84	251,
	(b) Provisions	850.97	870.
	(c) Deferred tax liabilities (Net)	3009.09	3065.8
		6528.90	4187.3
		2223.70	
	Current liabilities	1	I

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 14th
 November, 2017.
- 2. The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- 3. The Statutory Auditors have carried out a Limited review of the financial results for the quarter and half-year ended 30th September, 2017.
- 4. Previous year/period figures have been regrouped / rearranged wherever necessary.

Place: New Delhi

Date: 14th November, 2017

(a) Financial Liabilities
(i) Borrowings

(ii) Trade payables

(b) Other current liabilities

(c) Provisions

(iii) Other financial liabilities

TOTAL OF EQUITY AND LIABILITIES

INOPAGRASTHA
APOLO HOSELVIL THEP Gupta
STRIVATION
K.WEELHI Wahan ing Director

NEW DELHI

5604.91

10539.14

682.96

3689.36

20928.46

412.09

6481.01

326,08

1783.66

362.60

18969.13

46239,28

10015.78

S.N.Dhawan & CO. LLP

Chartered Accountants

Limited review report on Quarterly Financial Results and Year to date Results of the Company pursuant to the Regulation 33 of the SEBI (LODR) Regulations, 2015

To the Board of Directors
Indraprastha Medical Corporation Limited

We have reviewed the accompanying statement of unaudited financial results of Indraprastha Medical Corporation Limited ("the Company") for the quarter ended September 30, 2017 and the year to-date results for the period April 01, 2017 to September 30, 2017 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements (LODR)) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of Companies (Ind AS) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.



The comparative Ind AS financial information of the Company for the corresponding quarter September 30, 2016 and the corresponding year to date results for the period April 01, 2016 to September 30, 2016 and preceding quarter June 30, 2017 were reviewed by the predecessor auditor and the Ind AS financial statements of the Company for the year ended March 31, 2017 were audited by predecessor auditor who expressed an unmodified opinion on those financial information on November 22 2016, July 28 2017 and May 26, 2017 respectively.

For S.N. Dhawan & Co LLP

(Formerly S. N. Dhawan & Co.)

Chartered Accountants

Firm Registration No.: 000050N/N500045

NEW DELH

Rajeev K Saxena

Partner

Membership No.: 077974

Place: New Delhi

Date: November 14, 2017